Synthetic Biology-Based Therapies Summit 2022

Over the past couple of years, the engineered biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules and controllable therapeutics grows exponentially.

The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development.

Returning for the 2nd year, the Synthetic Biology-Based Therapies Summit is the industry-defining forum made exclusively for leaders in the synthetic and engineered biology space, focusing on the technical challenges that lie ahead in the path towards commercialization.

Learn from industry trailblazers at Arsenal Biosciences, bit.bio, MIT, Novome Bio, Strand Therapeutics, Synlogic and more, to support your efforts in developing safe and effective synthetic biology-based therapeutics.

Prices:
Conference + Workshop Day - Industry Pricing USD 3497.00
Conference Only - Industry Pricing USD 2599.00
Conference + Workshop Day - Service Provider Pricing USD 4297.00
Conference Only - Service Provider Pricing USD 3199.00
Conference + Workshop Day - Academic Pricing USD 2897.00
Conference Only - Academic Pricing USD 2199.00

Speakers: Matt Drever, Vice President, Molecular Biology & Protein Engineering, Arsenal Biosciences, Andrew Phillips, Director, Bioinformatics & Biologics Engineering, AstraZeneca, Mark Kotter, Founder & Chief Executive Officer, bit.bio, Edward Green, Founder & Chief Scientific Advisor, CHAIN Biotechnology, Adam Silverman, Senior Director, Therapeutic Discovery, Codexis, Marc Güell, Co-Founder & Scientific Lead, Integra Therapeutics, Qi Cai, Director, Cell Biology, Kite Pharma: A Gilead Company, Wenning Qin, Senior Vice President, Research, eGenesis Inc., Héctor Garcia Martin, Staff Scientist, Lawrence Berkeley National Laboratory, Lee Cooper, Senior Director, Venture Investments, Leaps by Bayer, Michael Hudson, Director, Synthetic Biology, LifeMine Therapeutics, Ron Weiss, Professor, Massachusetts Institute of Technology, Grant Murphy, Executive Director, Discovery Biologics, Merck & Co., Lauren Popov, Director, Translational Biology, Novome Biotechnologies, Samuel Schaffter, Bioengineer, National Institute of Standards & Technology, Tariq Warsi, Head of Technical Operations, Novome Biotechnologies, Jaspreet Khurana, Director, Platform & Discovery, Strand Therapeutics, Jonathan Winkler, Senior Director, Analytical Development, Seres Therapeutics, Russell Gordley, Senior Director, Gene Circuit Discovery, Senti Biosciences, Yu Qiu, Digital Biologics Advanced Application Lead, Sanofi, Anders Lund, Head of Analytical Development, Synlogic, Dave Hava, Chief Scientific Officer, Synlogic, David James, Chief Scientific Officer, SynGenSys, Jake Becraft, Co-Founder & Chief Executive Officer, Strand Therapeutics, Maria Soloveychik, Co-Founder & Chief Executive Officer, SyntheX, Ruben Vasquez-Uribe, Co-Principal Investigator of the Bacterial Synthetic Biology Section, The Novo Nordisk Foundation Center for Biosustainability, Stuart Licht, Scientific Director, Protein Science, Moderna, Synthego Representative, Synthego